Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
176 Leser
Artikel bewerten:
(1)

CenExel Research: CenExel Hosts Comprehensive Good Clinical Practice Training to Strengthen Clinical Excellence Across Network

NASHVILLE, TENNESSEE / ACCESS Newswire / November 20, 2025 / CenExel, a leading network of clinical research sites, is hosting a two-day Good Clinical Practice (GCP) training initiative beginning today, November 20, 2025, at the Sheraton Grand Nashville. Nearly 80 attendees, including Principal Investigators, sub-Investigators, regulatory and quality professionals, and clinical operations leaders, have gathered to enhance their understanding of the core regulatory and ethical standards that underpin every CenExel trial.

The training is facilitated by Deb Autor, JD, Elvira Cawthon, BS, MS, EMT-P, and Thom Mezak, MBA, PMP of Healthcare Innovation Catalysts, experts with extensive experience in regulatory compliance, data integrity, and investigator oversight. "Clinical research is rapidly evolving, but the core fundamental principles of GCP are still critical," said Deb, who is also a former FDA Deputy Commissioner. "By prioritizing this level of rigorous, hands-on training, CenExel is aiming to strengthen its future, elevating the quality of its trials and ensuring that every partner and patient can trust the work being done across the network."

Over the next two days, participants will explore key GCP principles, including ALCOA+++ data integrity, ICH GCP guidelines, and FDA and IRB regulations governing investigator responsibilities. The agenda also includes deep dives into Principal Investigator oversight, protocol compliance, adverse event reporting, and documentation standards, all of which are critical to maintaining the highest quality and ethical standards in clinical research.

"At CenExel, we hold ourselves to the highest level of scientific and regulatory excellence," said Ryan Brooks, CenExel's Chief Executive Officer. "This training reinforces our shared responsibility to sponsors, CROs, and - most importantly - our patients, ensuring that every study we conduct meets the highest standards of data integrity and participant safety."

Hollie DeSmet, Vice President of Regulatory & Quality Assurance at CenExel, also emphasized the importance of this endeavor by saying, "The Good Clinical Practice training underscores our unwavering commitment to regulatory compliance and quality assurance across the CenExel network. By investing in rigorous education for our investigators and operational teams, we reinforce the integrity of our research processes and safeguard the trust placed in us by sponsors and patients. This initiative ensures that every study we conduct adheres to the highest ethical and scientific standards, advancing our mission to deliver reliable data and improve patient outcomes."

Building on this foundation, the GCP training reflects CenExel's broader investment in staff development, operational consistency, and collaboration across its nationwide network of Centers of Excellence. By aligning investigators and quality professionals under a shared framework of compliance and best practices, CenExel strengthens its ability to deliver high-quality data and reliable results to its partners, supporting the company's mission to accelerate the development of new treatments through precise execution, trustworthy data, and the highest ethical standards.

Contact Information

Sara Koeblin
Director of Corporate Communications
s.koeblin@cenexel.com
(617) 639-6075

.

SOURCE: CenExel Research



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cenexel-hosts-comprehensive-good-clinical-practice-gcp-training-to-st-1103001

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.